Kali Therapeutics

News

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

News

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.